Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

Wednesday, May 16, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MISSISSAUGA, ON, May 16, 2018 /CNW/ - Effective May 15, 2018, the previously announced acquisition

by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. ("Cardiome") was completed by way of the acquisition by Cipher of all of the issued and outstanding common shares of Cardiome ("Common Shares
") following a restructuring of Cardiome pursuant to a court-approved plan of arrangement of Cardiome carried out under Section 192 of the Canada Business Corporations Act (the "Arrangement"). Pursuant to the Arrangement, shareholders of Cardiome prior to the effective date of the Arrangement received common shares, on a one-for-one basis, of a newly formed entity named Correvio Pharma Corp. Cipher and Cardiome's head office is located at 2345 Argentia Road, Suite 100A, Mississauga, Ontario.

Under the Arrangement, Cipher acquired ownership and control of an aggregate of 34,871,471 Common Shares (the "Acquisition"), representing 100% of the issued and outstanding Common Shares, at a deemed price of approximately $0.73 per Common Share for aggregate cash consideration of $25,500,000. Immediately prior to the completion of the Acquisition, Cipher did not hold any Common Shares.

The purpose of the Acquisition was to enable Cipher to acquire the Canadian business portfolio of Cardiome by way of the acquisition of all of the issued and outstanding Common Shares.

This news release is being issued in accordance with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the filing of an early warning report dated May 16, 2018 on the System for Electronic Document Analysis and Review ("SEDAR") under Cardiome's issuer profile at www.sedar.com.

SOURCE Cipher Pharmaceuticals Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store